Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
povidone-iodine + isopropyl alcohol + bupivacaine hydrochloride + lidocaine hydrochloride is a point-of-care combination kit that packages two amide local anesthetics with topical antiseptic skin-preparation agents for use around minor procedures requiring local or regional anesthesia. The anesthetic components, lidocaine hydrochloride and bupivacaine hydrochloride, act primarily by reversibly blocking voltage-gated sodium channels in peripheral nerves, thereby inhibiting initiation and propagation of action potentials and producing local anesthetic and analgesic effects; lidocaine generally provides faster onset while bupivacaine provides longer duration. The povidone-iodine and isopropyl alcohol components are included as topical antiseptics for skin preparation before injection or surgery. Products of this combination have been marketed by Asclemed USA for anesthesia-related use under kit brand names such as POINT OF CARE LM 2.5 and Marlido 25 Kit.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on povidone-iodine + isopropyl alcohol + bupivacaine hydrochloride + lidocaine hydrochloride.